Entrada Therapeutics (TRDA) to Release Earnings on Tuesday

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Entrada Therapeutics to post earnings of ($0.78) per share and revenue of $10.98 million for the quarter.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The firm had revenue of $12.25 million during the quarter, compared to analysts' expectations of $11.95 million. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Entrada Therapeutics Stock Down 0.9 %

TRDA stock traded down $0.08 during midday trading on Thursday, hitting $9.05. The company's stock had a trading volume of 102,568 shares, compared to its average volume of 126,268. The firm has a 50-day simple moving average of $9.61 and a 200-day simple moving average of $14.18. The firm has a market capitalization of $343.47 million, a P/E ratio of 5.69 and a beta of 0.04. Entrada Therapeutics has a 52-week low of $7.10 and a 52-week high of $21.79.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Monday, March 31st.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.